Welcome to our dedicated page for OCTAVE SPECIALTY GROUP SEC filings (Ticker: OSG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Octave Specialty Group, Inc. filings document the formal disclosure record for a specialty insurance company built around insurance distribution and underwriting businesses. Form 8-K reports cover quarterly results, P&C premium production, commission income, and segment commentary for Insurance Distribution and Everspan. Other current reports disclose material definitive agreements, including amendments to credit arrangements involving Octave subsidiaries and ArmadaCare-related borrowers.
Proxy filings cover annual meeting procedures, shareholder voting matters, board governance, and executive compensation. The record also includes capital-structure and governance disclosures for Octave common stock.
Octave Specialty Group Inc. reported an equity award to a board member in the form of restricted stock units. On January 1, 2026, the director received 4,524 restricted stock units (RSUs), each representing a contingent right to receive one share of Octave Specialty Group common stock. These RSUs are scheduled to vest on January 1, 2027. Once vested, they will convert into common shares on the earlier of the vesting date or the date the director leaves the company’s Board of Directors, unless the director elects to defer settlement. After this grant, the reporting person held a total of 8,650 derivative securities related to the company’s stock in direct ownership.
Octave Specialty Group Inc. reported an equity grant to a board member. A director received 4,524 restricted stock units (RSUs) of Octave Specialty Group Inc. common stock on January 1, 2026. Each RSU represents a right to receive one share of common stock and was granted at a price of $0 per unit. The RSUs are scheduled to vest on January 1, 2027. Once vested, they will convert into common shares on the earlier of the vesting date or the date the director ceases to serve on the company’s Board of Directors, unless the director elects to defer settlement. Following this grant, the reporting person holds 8,650 derivative securities directly.
Octave Specialty Group Inc. director and Chief Executive Officer reported buying additional company stock. On 01/02/2026, a Form 4 shows an open-market purchase of 12,000 shares of common stock at a price of $7.59 per share, coded as an acquisition transaction. After this trade, the reporting person beneficially owns 1,033,777 shares of Octave Specialty Group Inc. common stock in direct ownership. The filing reflects a single, straightforward insider purchase with no derivative securities activity disclosed.
Octave Specialty Group Inc. disclosed that one of its officers, serving as Senior Managing Director and General Counsel, filed an initial insider ownership report effective 12/11/2025.
The report states that this reporting person currently has no securities beneficially owned, and it was signed by attorney-in-fact William J. White on 12/17/2025.